
Boston Scientific statistics
$44.34+0.32%Close 13 Nov 2026 · Market value $63.86B
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
Boston Scientific is valued at $63.86B on its latest close. Its price is 18.2 times its earnings.
| Market value | $63.86B |
|---|
| Enterprise value | $75.86B |
|---|
| Price / earnings | 18.23 |
|---|
| Price / sales | 3.03 |
|---|
| Price / book | 2.49 |
|---|
| EV / EBITDA | 14.14 |
|---|
| EV / sales | 3.60 |
|---|
| Price / free cash flow | 19.17 |
|---|
| Price / free cash flow, own 5-year average | 55.45 |
|---|
| EV / EBIT | 19.13 |
|---|
| EV / free cash flow | 22.58 |
|---|
| Free cash flow yield | 5.2% |
|---|
Share price
| Latest close | $44.34 |
|---|
| Day's change | +0.3% |
|---|
| 52-week high | $105.65 |
|---|
| 52-week low | $39.57 |
|---|
| From 52-week high | −58.0% |
|---|
| Return · 1 month | −0.1% |
|---|
| Return · 3 months | −10.2% |
|---|
| Return · year to date | −53.5% |
|---|
| Return · 1 year | −57.4% |
|---|
| Beta · 1 year against the S&P 500 | 0.25 |
|---|
| 50-day average | $44.01 |
|---|
| 200-day average | $54.14 |
|---|
| RSI 14 | 50.4 |
|---|
| Average volume · 20 sessions | 20.1M |
|---|
Margins and returns
For fiscal 2025, as filed.
| Gross margin | 69.0% |
|---|
| Operating margin | 18.0% |
|---|
| Net margin | 14.4% |
|---|
| Free cash flow margin | 18.2% |
|---|
| Return on equity | 12.6% |
|---|
| Return on assets | 7.4% |
|---|
| Return on invested capital | 8.6% |
|---|
| Return on invested capital, 5-year average | 5.9% |
|---|
| Return on capital employed | 10.1% |
|---|
| Stock-based compensation / revenue | 1.5% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $1.97B |
|---|
| Total debt | $11.97B |
|---|
| Net debt | $10.01B |
|---|
| Current ratio | 1.62 |
|---|
| Quick ratio | 0.10 |
|---|
| Debt / equity | 0.49 |
|---|
| Net debt / EBITDA | 2.01 |
|---|
| Interest coverage | 10.35 |
|---|
Growth
| Revenue, latest quarter on a year | +1.4% |
|---|
| Revenue, twelve months on a year | +8.9% |
|---|
| EPS, latest quarter on a year | −21.6% |
|---|
| EPS, twelve months on a year | +26.6% |
|---|
| Revenue, 5-year compound | +15.2% |
|---|
| Revenue, 10-year compound | +9.5% |
|---|
| Free cash flow, 5-year compound | +26.4% |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 1.5B |
|---|
| Shares outstanding, 5-year compound | +1.1% |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $493.0M |
|---|
| Effective tax rate | 14.6% |
|---|
BSX in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.